Cipla's Q1 FY 2025-26 Quarterly Results

Result Summary

• Cipla Ltd reported a 12.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 5.3%.
• Its expenses for the quarter were up by 5.7% QoQ and 3.9% YoY.
• The net profit increased 38.6% QoQ and increased 9.9% YoY.
• The earnings per share (EPS) of Cipla Ltd stood at 16.1 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Cipla Ltd is a prominent pharmaceutical company based in India, known for its wide range of pharmaceutical products. The company's offerings include prescription drugs, over-the-counter medications, and a variety of healthcare products. Cipla is recognized for its generic formulations, contributing significantly to its revenue base. Operating within the healthcare and pharmaceutical industry, Cipla has established itself as a key player, both domestically and internationally. Recent developments in the industry, such as advancements in biotechnology and increased demand for generic medicines, are relevant to Cipla's business environment. Specific recent developments for Cipla were not provided in the data.

Revenue

In Q1FY26, Cipla Ltd reported a total income of ₹7216.03 crores, marking a quarter-over-quarter (QoQ) increase of 12.5% from ₹6412.57 crores in Q4FY25. Year-over-year (YoY), the total income rose by 5.3% from ₹6854.13 crores in Q1FY25. This growth in revenue indicates the company's ability to generate increased income over both the previous quarter and the same quarter in the previous year. The revenue data suggests a positive trajectory in sales or services provided by Cipla over the analyzed periods.

Profitability

Cipla's profitability metrics for Q1FY26 demonstrate a robust performance. The profit before tax (PBT) is recorded at ₹1769.93 crores, which shows a significant QoQ increase of 40.6% from ₹1259.26 crores in Q4FY25, and a YoY increase of 9.8% from ₹1611.36 crores in Q1FY25. After accounting for taxes, the profit after tax (PAT) for Q1FY26 stands at ₹1291.61 crores, reflecting a 38.6% QoQ growth from ₹931.87 crores in Q4FY25 and a 9.9% YoY growth from ₹1175.46 crores in Q1FY25. The earnings per share (EPS) also saw substantial growth, with a 38.8% QoQ increase from 11.60 to 16.10 and a 10.3% YoY increase from 14.60. These metrics indicate improved profitability over the analyzed periods.

Operating Metrics

The total expenses for Cipla in Q1FY26 were ₹5446.10 crores, reflecting a 5.7% QoQ increase from ₹5153.31 crores in Q4FY25 and a 3.9% YoY increase from ₹5242.77 crores in Q1FY25. The tax expense for the quarter was ₹477.88 crores, showing a 47.1% QoQ increase from ₹324.86 crores in Q4FY25 and a 9.8% YoY increase from ₹435.07 crores in Q1FY25. These figures demonstrate a rise in both operational and tax-related outflows, correlating with the company's increased profitability and income. The financial ratios like P/E, debt-to-equity, and current ratios were not provided in the data. The observed trends in expenses and tax align with the company's revenue and profit growth over the periods analyzed.